Relmada Therapeutics (RLMD) Treasury Shares (2016 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Treasury Shares data on file, last reported at $8.0 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $8.0 million, up 817.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 817.41% YoY), and the FY2025 annual result was $5.9 million, up 325.29% from the prior year.
• Treasury Shares advanced to $8.0 million in Q1 2026 per RLMD's latest filing, from $5.9 million in the prior quarter.
• Over five years, Treasury Shares peaked at $8.0 million in Q1 2026 and troughed at $750908.0 in Q2 2025.
• A 5-year average of $2.7 million and a median of $1.7 million in 2024 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2025 and 2026: Treasury Shares slumped 54.86% in 2025, then surged 817.41% in 2026.
• A 5-year view of Treasury Shares shows it stood at $3.0 million in 2022, then fell by 21.34% to $2.4 million in 2023, then tumbled by 41.94% to $1.4 million in 2024, then surged by 325.29% to $5.9 million in 2025, then soared by 36.19% to $8.0 million in 2026.
• Business Quant data shows RLMD's Treasury Shares at $8.0 million in Q1 2026, $5.9 million in Q4 2025, and $750908.0 in Q3 2025.